Lower intensity regimens for acute myeloid leukemia: opportunities and challenges

References

• Tallman MS, Wang ES, Altman JK, et al. Acute myeloid leukemia, version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(6):721–749.
   PubMed Web of Science ®Google Scholar
• Bazinet A, Kadia TM. Changing paradigms in the treatment of acute myeloid leukemia in older patients. Clin Adv Hematol Oncol. 2022;20(1):37–46.
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid leukaemia in the elderly: a review. Br J Haematol. 2011;152(5):524–542.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute SP. Cancer Stat Facts: leukemia – acute myeloid leukemia (AML). Available from: https://seer.cancer.gov/statfacts/html/amyl.html
   Google Scholar
• Yates JW, Wallace HJ Jr., Ellison RR, et al. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 1973;57(4):485–488.
   PubMedGoogle Scholar
• Getta BM, Ghosh A, Coombs CC, et al. TP53 mutations in AML predict adverse outcome in patients undergoing allogeneic hematopoietic stem cell transplant. Blood. 2016;128(22):3481.
   Google Scholar
• Jackson KA, Kennedy GA, Mollee P, et al. Intensive chemotherapy for acute myeloid leukemia in elderly patients. Blood. 2012;120(21):4341.
   Google Scholar
• Hupfer V, Grishina O, Schmoor C, et al. Validation of a frailty score predicting survival of elderly, non-fit AML patients receiving hypomethylating therapy: results of the decider trial. Blood. 2018;132(Suppl. 1):720.
   Google Scholar
• Olin RL. Delivering intensive therapies to older adults with hematologic malignancies: strategies to personalize care. Hematology Am Soc Hematol Educ Program. 2019;2019(1):63–70.
   PubMedGoogle Scholar
• de Almeida LB, Mira PAC, Fioritto AP, et al. Functional capacity change impacts the quality of life of hospitalized patients undergoing hematopoietic stem cell transplantation. Am J Phys Med Rehabil. 2019;98(6):450–455.
   PubMed Web of Science ®Google Scholar
• Récher C, Röllig C, Bérard E, et al. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries. Leukemia. 2022;36(4):913–922.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
   PubMed Web of Science ®Google Scholar
• Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137–2145.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Wei AH. How I treat acute myeloid leukemia in the era of new drugs. Blood. 2020;135(2):85–96.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33(2):379–389.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386–2398.
   PubMed Web of Science ®Google Scholar
• Montesinos P, Recher C, Vives S, et al. AGILE: a global, randomized, double-blind, phase 3 study of ivosidenib + azacitidine versus placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation. Blood. 2021;138(Suppl. 1):697.
   Google Scholar
• Aldoss I, Pullarkat V, Stein AS. Venetoclax-containing regimens in acute myeloid leukemia. Ther Adv Hematol. 2021;12:2040620720986646.
   Web of Science ®Google Scholar
• Thomas ED, Lochte HL Jr., Lu WC, et al. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med. 1957;257(11):491–496.
   PubMed Web of Science ®Google Scholar
• Wall SA, Devine S, Vasu S. The who, how and why: allogeneic transplant for acute myeloid leukemia in patients older than 60 years. Blood Rev. 2017;31(6):362–369.
   PubMed Web of Science ®Google Scholar
• Scott BL, Pasquini MC, Logan BR, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35(11):1154–1161.
   PubMed Web of Science ®Google Scholar
• Craddock C, Jackson A, Loke J, et al. Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia. J Clin Oncol. 2021;39(7):768–778.
   PubMed Web of Science ®Google Scholar
• Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–650.
   PubMed Web of Science ®Google Scholar
• Song Y, Yin Z, Ding J, et al. Reduced intensity conditioning followed by allogeneic hematopoietic stem cell transplantation is a good choice for acute myeloid leukemia and myelodysplastic syndrome: a meta-analysis of randomized controlled trials. Front Oncol. 2021;11:708727.
   PubMed Web of Science ®Google Scholar
• Devillier R, Galimard JE, Labopin M, et al. Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. Bone Marrow Transplant. 2022;57(9):1421–1427.
   PubMed Web of Science ®Google Scholar
• Beelen DW, Trenschel R, Stelljes M, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematol. 2020;7(1):e28–e39.
   PubMed Web of Science ®Google Scholar
• Yu J, Du Y, Ahmad S, et al. Comparison of myeloablative versus reduced-intensity conditioning regimens in allogeneic stem cell transplantation recipients with acute myelogenous leukemia with measurable residual disease-negative disease at the time of transplantation: a retrospective cohort study. Transplant Cell Ther. 2021;27(8):663.e1–663.e6.
   PubMedGoogle Scholar
• Hourigan CS, Dillon LW, Gui G, et al. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2020;38(12):1273–1283.
   PubMed Web of Science ®Google Scholar